Clinical Report: CRISPR Enables In Vivo CAR T Cell Production

Overview

A novel CRISPR-based method allows for the in vivo production of CAR T cells, potentially streamlining cell therapy manufacturing. This approach utilizes a two-vector system to insert therapeutic genes directly into T cells, achieving significant anti-tumor effects in humanized mouse models.

Background

The development of CAR T cell therapies has revolutionized the treatment of various hematologic malignancies. However, the current ex vivo manufacturing process is complex and costly, limiting access to these therapies. Innovations like in vivo CAR T cell production could enhance efficiency and reduce barriers to treatment.

Data Highlights

The study demonstrated that the CRISPR-based system generated substantial populations of CAR T cells in vivo, achieving therapeutic levels and effectively depleting B cells in humanized mouse models.

Key Findings

• The two-vector system combines CRISPR-Cas9 and engineered AAV for targeted gene insertion.
• CAR genes were inserted into the TRAC locus, ensuring T cell-specific expression.
• The engineered delivery vehicles showed improved specificity and efficiency in targeting T cells.
• The resulting CAR T cells exhibited strong proliferation and anti-tumor activity across various cancer models.
• This method could significantly reduce costs and improve access to CAR T therapies if translated to human applications.

Clinical Implications

The ability to produce CAR T cells in vivo may simplify the treatment process and lower costs, making these therapies more accessible to patients. Clinicians should stay informed about these advancements as they could change the landscape of CAR T cell therapy.

Conclusion

The CRISPR-based in vivo CAR T cell production represents a promising advancement in cell therapy, potentially overcoming existing manufacturing challenges and enhancing patient access to effective treatments.

References

1. Franklin / MDSpire, Current Ex Vivo CAR-T Benchmarks Define the Bar for Emerging In Vivo CRISPR-Based T Cell Engineering
2. The ASCO Post, New Data on ALK Inhibitors and CAR T-Cell Therapies
3. the medicine maker, Breaking the Size Barrier in CAR T Engineering
4. The ASCO Post, CRISPR-Edited, Off-the-Shelf CAR T-Cell Therapy Shows Proof of Concept in Renal Cell Carcinoma
5. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
6. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - PubMed
7. In vivo chimeric antigen receptor (CAR)-T cell therapy | Nature Reviews Drug Discovery
8. Franklin / MDSpire — Current Ex Vivo CAR-T Benchmarks Define the Bar for Emerging In Vivo CRISPR-Based T Cell Engineering
9. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
10. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial - PubMed
11. In vivo chimeric antigen receptor (CAR)-T cell therapy | Nature Reviews Drug Discovery